Abstracts tagged "body mass and psoriatic arthritis"

Abstract Number: 609 • 2017 ACR/ARHP Annual Meeting
Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial
Iain B. McInnes¹, Gianfranco Ferraccioli², MA D'Agostino³, M Le Bars⁴, S Banerjee⁵, H Ahmad⁵, Y Elbez⁶, J Ye⁵ and Philip J Mease⁷, ¹University of Glasgow, Glasgow, Great Britain, ²Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Hôpital Ambroise Paré, Boulogne-Billancourt, France, ⁴Bristol-Myers Squibb, Rueil-Malmaison, France, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Excelya, Boulogne-Billancourt, France, ⁷Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Obesity is a risk factor for the development and severity of psoriatic arthritis (PsA).1,2 Patients (pts) with increased BMI (overweight/obese) are less likely to…
Abstract Number: 666 • 2015 ACR/ARHP Annual Meeting
Disease Activity Indices and Body Mass Index: Cross-Sectional Analysis of a Large Psoriatic Arthritis Cohort
Umut Kalyoncu¹, Ozun BayndÄ±r¹, Barış Yılmazer¹, Ediz Dalkilic², Kenan Aksu¹, Mustafa Ferhat Oksuz¹, E.Figen Tarhan¹, Meryem Can¹, Orhan Kucuksahin¹, Gezmis Kimyon¹, Lutfi Akyol¹, Ahmet Mesut Onat¹, Bunyamin Kisacik¹, Abdulsamet Erden¹, Ahmet Omma¹, Duygu Ersozlu Bakirli¹, Cem Ozisler¹, Emel Gonullu¹, Seval Pehlevan¹, Dilek Solmaz¹, Muhammet Cinar¹, Gozde Cetin¹, Abdurrahman Tufan¹, Muge Aydin Tufan¹, Levent Kilic¹, Sukran Erten¹, Timucin Kasifoglu¹, Senol Kobak¹, Soner Senel¹, Servet Akar¹, Metin Ozgen¹, Esen Kasapoglu-Gunal¹, Veli Yazisiz¹, Sedat Yılmaz¹, Salim Donmez¹, Ä°smail Dogan¹, Hamide Kart Koseoglu¹, Funda Erbasan¹, Fatih Yildiz¹, Cemal Bes¹, Ayse Balkarli¹, Ali Sahin¹, Rıdvan Mercan¹, Fatoş Arslan¹, Atalay Dogru¹, Salih Pay¹, Sule Yavuz¹, Necati Cakir¹, Yasemin Kabasakal¹ and Sibel Z. Aydin¹, ¹PsART study group, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Well known comorbidities of Psoriatic arthritis (PsA) such as cardiovascular disease, metabolic syndrome and diabetes mellitus are closely related with body mass index (BMI).…
Abstract Number: 2884 • 2015 ACR/ARHP Annual Meeting
Epidemiological Parameters Affecting Therapeutic Response in Psoriatic Arthritis Patients
Michail P. Migkos¹, George Somarakis², Evripidis Kaltsonoudis³, Theodora E. Markatseli⁴, Paraskevi V. Voulgari^5,6 and Alexandros A. Drosos⁷, ¹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Fellow in Rheumatology, Ioannina, Greece, ²Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, ³Rheumatology Clinic, Department of Internal Medicine, Rheumatologist, Ioannina, Greece, ⁴Rheumatology Clinic, Department of Internal Medicine, Fellow in Rheumatology, Ioannina, Greece, ⁵Rheumatology Clinic, Department of Internal Medicine, Assistant Professor of Rheumatology, Ioannina, Greece, ⁶Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Assistant Professor of Rheumatology, Ioannina, Greece, ⁷Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Professor of Medicine/Rheumatology, Ioannina, Greece
Background/Purpose: Published data have shown that epidemiological parameters such as Body Mass Index (BMI), gender and disease duration may affect the therapeutic response in psoriatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].